US 6,444,859 B1Granted

Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid

AssigneesAbbott Laboratories, Central Glass Company, Limited

InventorsChristopher Bieniarz, Steve H. Chang, Keith R. Cromack, Shuyen L. Huang, Toshikazu Kawai, Manami Kobayashi, David Loffredo, Rajagopalan Raghavan, Earl R. Speicher, Honorate A. Stelmach

Life of this patent

Estimating the term…

Abstract

The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.

Claims6

Dependent claims

A method for preventing degradation by Lewis acids of a quantity of sevoflurane, said method comprising providing a quantity of sevoflurane and contacting said quantity of sevoflurane with an amount of Lewis acid inhibitor, said amount of Lewis acid inhibitor being selected such that said Lewis acid inhibitor is present in an amount of at least 150 parts per million parts of a total of said quantity of sevoflurane and said amount of Lewis acid inhibitor.

Dependencies are inferred from the claim text.

Facts

Application: 09/924,573Filed 8 Aug 2001 · continuation
Priority: 27 Jan 1997
Published: US 2002/0016373 A17 Feb 2002
Granted: 3 Sep 2002
Term ends: Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 47/02
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents…:…
A61K 31/08
Ethers or acetals: acyclic, e.g. paraformaldehyde
A61K 47/10
Containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides: alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene…
A61K 47/12
Containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides: carboxylic acids; Salts or anhydrides thereof

Family

Application08/789,679Parent of this continuation · filed 27 Jan 1997
Application09/447,853Parent of this continuation · filed 23 Nov 1999
US 6,288,127 B1Parent of this continuation
US 5,990,176 AParent of this continuation
US 2002/0016373 A1Published application
US 6,444,859 B1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

Facts

Application

09/924,573Filed 8 Aug 2001 · continuation

Priority

27 Jan 1997

Published

US 2002/0016373 A17 Feb 2002

Granted

3 Sep 2002

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 47/02
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents…:…
A61K 31/08
Ethers or acetals: acyclic, e.g. paraformaldehyde
A61K 47/10
Containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides: alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene…
A61K 47/12
Containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides: carboxylic acids; Salts or anhydrides thereof

Family

Application08/789,679Parent of this continuation · filed 27 Jan 1997

Application09/447,853Parent of this continuation · filed 23 Nov 1999

US 6,288,127 B1Parent of this continuation

US 5,990,176 AParent of this continuation

US 2002/0016373 A1Published application

US 6,444,859 B1This patent

From the US filing history. Foreign family members aren’t listed.